133464-37-6

Basic information

• Product Name: (R)-BENZYL 4-FORMYL-2,2-DIMETHYLOXAZOLIDINE-3-CARBOXYLATE
• Synonyms: (R)-BENZYL 4-FORMYL-2,2-DIMETHYLOXAZOLIDINE-3-CARBOXYLATE
• CAS NO: 133464-37-6
• Molecular Formula: C₁₄H₁₇NO₄
• Molecular Weight: 263.29
• Mol File: 133464-37-6.mol

Chemical Properties

• Boiling Point: 390.2±42.0 °C(Predicted)
• Appearance: /
• Density: 1.229±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: -3.31±0.60(Predicted)
• CAS DataBase Reference: (R)-BENZYL 4-FORMYL-2,2-DIMETHYLOXAZOLIDINE-3-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-BENZYL 4-FORMYL-2,2-DIMETHYLOXAZOLIDINE-3-CARBOXYLATE(133464-37-6)
• EPA Substance Registry System: (R)-BENZYL 4-FORMYL-2,2-DIMETHYLOXAZOLIDINE-3-CARBOXYLATE(133464-37-6)

Safety Data

• Hazardous Substances Data: 133464-37-6(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
(R)-Benzyl 4-formyl-2,2-dimethyloxazolidine-3-carboxylate is used as a building block for constructing more complex molecules, contributing to the development of advanced organic compounds and materials.
Used in Pharmaceutical Research:
As a chiral molecule, (R)-Benzyl 4-formyl-2,2-dimethyloxazolidine-3-carboxylate is used in pharmaceutical research for the development of new drugs, potentially offering novel therapeutic agents and enhancing the effectiveness of existing medications.
Used as a Reagent in Chemical Reactions:
(R)-Benzyl 4-formyl-2,2-dimethyloxazolidine-3-carboxylate serves as a reagent in various chemical reactions, facilitating the synthesis of target compounds and contributing to the advancement of chemical processes and methodologies.

Upstream product

• 133464-35-4 3-benzyl 4-methyl (4R)-2,2-dimethyloxazolidine-3,4-dicarboxylate 
• 133464-36-5 (S)-hydroxymethyl-2,2-dimethyloxazolidine-3-carboxylic acid benzyl ester 
• 93204-36-5 (R)-methyl 2-(((benzyloxy)carbonyl)amino)-3-hydroxypropanoate 
• 501-53-1 benzyl chloroformate 
• 656827-13-3 (R)-benzyl-4-(methoxy(methyl)carbamoyl)-2,2-dimethyloxazolidine-3-carboxylate 
• 6081-61-4 N-(benzyloxycarbonyl)-D-serine 
• 77-76-9 2,2-dimethoxy-propane 
• 1092473-80-7 (R)-benzyl 3-hydroxy-1-(methoxy(methyl)amino)-1-oxopropane-2-ylcarbamate 

Downstream Products

• 137787-29-2 (R)-2,2-Dimethyl-4-((S)-2,2,2-trichloro-1-hydroxy-ethyl)-oxazolidine-3-carboxylic acid benzyl ester 
• 324027-10-3 (R)-4-[(4-Bromo-phenyl)-hydroxy-methyl]-2,2-dimethyl-oxazolidine-3-carboxylic acid benzyl ester 
• 366469-80-9 (R)-4-(Hydroxy-phenyl-methyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid benzyl ester 
• 433235-59-7 (R)-4-[(R)-((3R,7aR)-3-tert-Butyl-1-oxo-dihydro-pyrrolo[1,2-c]oxazol-7a-yl)-hydroxy-methyl]-2,2-dimethyl-oxazolidine-3-carboxylic acid benzyl ester 
• 433238-14-3 (R)-4-[(S)-((3R,7aR)-3-tert-Butyl-1-oxo-dihydro-pyrrolo[1,2-c]oxazol-7a-yl)-hydroxy-methyl]-2,2-dimethyl-oxazolidine-3-carboxylic acid benzyl ester 
• 408359-25-1 (3E)-5-amino-1-C-(2,3,4,6-tetra-O-benzyl-α-D-glucopyranosyl)-5-N-benzyloxycarbonyl-1,3,4,5-tetradeoxy-5,6-N,O-isopropylidene-D-glycero-hex-3-eno-2-ulose 
• 510713-88-9 (4R)-4-[(1RS)-2-ethoxycarbonyl-2,2-difluoro1-hydroxyethyl]-2,2-dimethyloxazolidine-3-carboxylic acid benzyl ester 
• 873310-64-6 2S-(3-benzyloxycarbonyl-2,2-dimethyloxazolidin-4-ylmethylene)-malonic acid di-tert-butyl ester 
• 912354-37-1 (2S)-2-(2-benzyloxycarbonylamino-3-hydroxypropyl)malonic acid di-tert-butyl ester 
• 912354-29-1 (4S)-2-(3-benzyloxycarbonyl-2,2-dimethyloxazolidin-4-ylmethyl)malonic acid di-tert-butyl ester 
• 945034-94-6 2-(2-benzyloxycarbonylamino-3-oxo-propyl)-2-tert-butoxycarbonyl-succinic acid di-tert-butyl ester 
• 873310-65-7 2S-(2-benzyloxycarbonylamino-3-hydroxy-propylidene)-malonic acid di-tert-butyl ester 
• 873310-66-8 4-benzyloxycarbonylamino-2-tert-butoxycarbonyl-pent-2-enedioic acid 1-tert-butyl ester 
• 444184-02-5 [(1R,2S)-2-(2-Amino-phenyl)-2-hydroxy-1-hydroxymethyl-ethyl]-carbamic acid benzyl ester 

Relevant articles and documents

A simple convenient synthesis of L-[4-13C] glutamine

L-[4-13C]Glutamine was synthesized from sodium [2-13C]acetate in 12 steps and 18% overall yield. A Wittig reaction of (R)-benzyl 4-formyl-2,2-dimethyloxazolidine-3-carboxylate and ethyl 2-(triphenylphosphoranylidene)[2-13C]acetate prepared from D-serine and sodium [2-13C]acetate, respectively, gave (4S)-4-(2-ethoxycarbonyl[2-13C]vinyl)-2,2-dimethyloxazolidine-3-carboxylic acid α,β-isopropylidene group, oxidation of the resulting hydroxyl group to a carboxyl group and transamidation of the ester moiety gave L-N-Cbz-[4-13C]glutamine (Cbz = benzyloxycarbonyl). Finally, removal of the Cbz group gave L-[4-13C]glutamine. L-[4-13C]Glutamine can be prepared in fewer steps and higher yield by this method compared with previously reported methods.

Tetrahydroisoquinoline intermediate of compound preparation method

The invention provides a tetrahydroisoquinoline compound with the following structural general formula I. The invention also provides application of the above tetrahydroisoquinoline compound as an intermediate for the preparation of tetrahydroisoquinoline alkaloid natural medicaments. The invention further provides a method for preparing the tetrahydroisoquinoline compound. The method uses a halogenated aromatic compound as a starting material, and conducts nucleophilic substitution, addition, hydroxy elimination and protecting group elimination reaction, thereby obtaining the tetrahydroisoquinoline compound with chiral amine.

METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES

PROBLEM TO BE SOLVED: To provide a method of treating polycystic kidney diseases with ceramide derivatives. SOLUTION: A pharmaceutical composition for treating polycystic kidney disease in a subject comprises an effective amount of a predetermined compoun

Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease

A method of treating a glomerular disease selected from the group consisting of mesangial proliferative glomerulonephritis, collapsing glomerulopathy, proliferative lupus nephritis, crescentic glomerulonephritis and membranous nephropathy in a subject com

DDQ-Promoted Benzylic/Allylic sp3 C-H Activation for the Stereoselective Intramolecular C-N Bond Formation: Applications to the Total Synthesis of (-)-Codonopsinine, (+)-5-epi-Codonopsinine, (+)-Radicamine B, and (-)-Codonopsinol

This is the first report on an intramolecular C-N bond formation of an amide-tethered benzylic/allylic system using DDQ under neutral conditions which has been successfully applied to the total synthesis of naturally occurring pyrolidine alkaloids. The key steps for the synthesis of corresponding precursors involve Julia-Kociensky olefination/cross-metathesis and dihydroxylation reactions, and this methodology is also extended to the ω-unsaturated N-sulfanilamide to furnish piperidines.

2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS

A compound for use in treating polycystic kidney disease is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating polycystic kidney disease in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. Methods of treating in polycystic kidney disease in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof

4,4-Difluorinated analogues of l-arginine and NG-hydroxy-l-arginine as mechanistic probes for nitric oxide synthase

4,4-Difluoro-l-arginine and 4,4-difluoro-NG-hydroxy-l-arginine were synthesized and shown to be substrates for the inducible isoform of nitric oxide synthase (iNOS). Binding of both fluorinated analogues to the NOS active site was also investigated using a spectral binding assay employing a heme domain construct of the inducible NOS isoform (iNOSheme). 4,4-Difluoro-NG-hydroxy-arginine was found to bind at the NOS active site in a unique manner consistent with a model involving ligation of the FeIII heme center by the oxygen atom of the NG-hydroxy moiety.

2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS

A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating

Design and concise synthesis of fully protected analogues of L-γ-carboxyglutamic acid

The design and synthesis of four nonnaturally occurring amino acid analogues of L-γ-carboxyglutamic acid (Gla), appropriately protected for Fmoc-based solid-phase peptide synthesis (SPPS), is described. These amino acids are Bu-Mal 2, BCAH 3, Pen-Mal 4, a

The synthesis of (2S)-4,4-difluoroglutamyl γ-peptides based on Garner's aldehyde and fluoro-reformatsky chemistry

The development of optically active fluorinated synthetic building blocks of general utility is a current goal of organo-fluorine chemists. The serine-derived Garner aldehyde was converted to a general 4,4-difluoroamino acid building block via fluoro-Reformatsky reaction with ethyl bromodifluoroacetate. The utility of this building block was demonstrated by the synthesis of derivatives of (2S)-4,4-difluoroglutamine, (2S)-4,4-difluoroglutamic acid, and its incorporation into a fluorophore-containing isopeptide 2 designed as a mechanistic probe of γ-glutamyl hydrolase. Compound 2 proved to be a substrate for γ-glutamyl hydrolase and was hydrolyzed at a rate significantly slower than the corresponding non-fluorinated analog.